Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
Pohar R, Nkansah E
Record ID 32011001215
English
Authors' recommendations:
Based on the evidence, the use of 131I-tositumomab and 90Y-ibritumomab may be treatment options for patients with refractory or relapsed NHL. The guidelines recommended the use of these drugs in patients with NHL that is refractory to chemotherapy. The cost-effectiveness information, which was not presented from a Canadian perspective, suggeststhat the use of 131I-tositumomab may be a cost-effective option during third- or fourth-line NHL treatment, depending on a third-party payer’s willingness to pay for a quality-adjusted life year.The evidence suggests that the use of 131I-tositumomab and 90Y-ibritumomab be reserved for individuals with follicular NHL whose initial treatment fails to produce a response.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Immunotherapy
- Lymphoma, Non-Hodgkin
- Radioimmunotherapy
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.